US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
BMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p587 (Published 14 March 2023) Cite this as: BMJ 2023;380:p587In this paper by Lalani and colleagues (BMJ 2023;380:e073747, doi:10.1136/bmj-2022-073747, published 1 March 2023), a transcription error before submission led to inconsistency between the text under “Pandemic funding” relating to the amounts of money received by Moderna and Pfizer-BioNTech and the supplementary data presented in eTable 4. The relevant sentences should now read: “Moderna received $10.8bn, of which $8.8bn (81%) was for vaccine supply. Pfizer-BioNTech received $20.4bn, mostly for vaccine supply.”
The data are accurate, and the text has now been corrected.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.